DDInter1589 DDInter899
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
Rifabutin {u} (Compound) upregulates {v} (Gene) MAL
Rifabutin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifabutin {u} (Compound) downregulates {v} (Gene) CDC20
Rifabutin {u} (Compound) causes {v} (Side Effect) Neutropenia
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Rifabutin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Rifabutin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Rifabutin (Compound) resembles Rifampicin (Compound)
Rifabutin (Compound) resembles Rifapentine (Compound)
Rifabutin (Compound) binds CYP3A4 (Gene)
Rifabutin (Compound) upregulates MAL (Gene)
Rifabutin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifabutin (Compound) downregulates CDC20 (Gene)
Rifabutin (Compound) causes Neutropenia (Side Effect)
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Miconazole
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib